Intervertebral Disc Disease

Intervertebral disc disease (IVDD) is a common neurological disorder in dogs, characterized by degeneration, protrusion, or extrusion of the intervertebral discs, leading to spinal cord compression, contusion, and ischemia. The intervertebral discs are fibrocartilaginous structures located between the vertebrae, providing shock absorption and flexibility to the spine. IVDD encompasses two main types: Hansen type I, which involves chondroid metaplasia and acute disc extrusion, commonly seen in chondrodystrophic breeds (e.g., Dachshunds, Beagles, French Bulldogs), and Hansen type II, which involves fibroid degeneration and chronic disc protrusion, typically seen in non-chondrodystrophic breeds (e.g., Labrador Retrievers, German Shepherds). The disease can affect any spinal region but most commonly occurs in the thoracolumbar (T11-L2) and cervical (C2-C7) regions. Clinical signs range from spinal pain to severe neurological deficits, including paresis, paralysis, and loss of deep pain perception. IVDD is a leading cause of spinal cord injury in dogs and requires prompt diagnosis and management to optimize outcomes.

The primary etiology of IVDD is multifactorial, involving genetic predisposition, biomechanical stress, and age-related degeneration. In chondrodystrophic breeds, a mutation in the FGF4 retrogene on chromosome 12 is strongly associated with early-onset disc degeneration, leading to chondroid metaplasia. This process results in the replacement of the nucleus pulposus with hyaline cartilage, which calcifies and becomes prone to acute extrusion. In non-chondrodystrophic breeds, fibroid degeneration occurs, characterized by replacement of the nucleus pulposus with fibrous tissue, leading to chronic disc protrusion. Other contributing factors include trauma, obesity, and repetitive spinal loading. Secondary causes such as spinal trauma, neoplasia, or infection can mimic IVDD but are not primary etiologies. The exact molecular triggers involve matrix metalloproteinases, inflammatory cytokines, and oxidative stress, which degrade the extracellular matrix of the disc.

IVDD is most prevalent in dogs, with a higher incidence in chondrodystrophic breeds. Dachshunds have a lifetime risk of 19-24%, with peak onset between 3 and 6 years of age. Other predisposed breeds include Beagles, Shih Tzus, Pekingese, French Bulldogs, and Corgis. Non-chondrodystrophic breeds, such as Labrador Retrievers, German Shepherds, and Golden Retrievers, typically develop IVDD later in life (8-10 years) and often present with Hansen type II disease. There is no significant sex predilection, although some studies suggest a slight male predominance. The condition is rare in cats, with a prevalence of less than 0.5%, and when it occurs, it is usually in older cats with concurrent spondylosis. Geographic variation is minimal, but obesity and lack of exercise are recognized risk factors. The incidence of IVDD has been increasing in recent years, possibly due to improved diagnostic imaging and increased awareness.

The pathophysiology of IVDD involves a cascade of degenerative changes in the intervertebral disc. In Hansen type I, chondroid metaplasia leads to calcification of the nucleus pulposus, which loses its water content and becomes less resilient. Acute trauma or minor stress can cause the nucleus pulposus to rupture through the annulus fibrosus, resulting in explosive extrusion of disc material into the vertebral canal. This causes spinal cord contusion and compression, leading to primary mechanical injury and secondary vascular and biochemical damage. The spinal cord undergoes hemorrhage, edema, and ischemia, with subsequent release of excitatory amino acids, free radicals, and inflammatory cytokines, exacerbating neuronal injury. In Hansen type II, fibroid degeneration causes gradual protrusion of the annulus fibrosus, leading to chronic spinal cord compression. This results in progressive demyelination, axonal degeneration, and gliosis. The severity of neurological deficits correlates with the degree of spinal cord compression and the rate of onset. In severe cases, loss of deep pain perception indicates irreversible spinal cord damage.

Predisposing factors for IVDD include genetic susceptibility, particularly the FGF4 retrogene in chondrodystrophic breeds. Age is a significant factor, with peak incidence in middle-aged dogs. Obesity increases the mechanical load on the spine, accelerating disc degeneration. High-impact activities, such as jumping or stair climbing, can precipitate disc extrusion in predisposed dogs. Concurrent conditions, such as spondylosis deformans, may alter spinal biomechanics and increase the risk. Endocrine disorders, such as hypothyroidism, have been suggested as potential risk factors, though evidence is limited. Environmental factors, including lack of regular exercise and poor muscle conditioning, may contribute to spinal instability. Additionally, a history of previous spinal trauma or prior IVDD episodes increases the likelihood of recurrence.

Clinical signs of IVDD vary depending on the location and severity of spinal cord involvement. In thoracolumbar IVDD, signs range from mild spinal pain (Grade 1) to non-ambulatory paraparesis (Grade 3) and paraplegia with loss of deep pain perception (Grade 5). Pain may be elicited on palpation of the spine, and dogs may exhibit kyphosis, reluctance to move, or vocalization. Neurological deficits include proprioceptive ataxia, paresis, and paralysis. In cervical IVDD, signs include neck pain, stiffness, and reluctance to lower the head. Severe cervical lesions can cause tetraplegia and respiratory compromise. Autonomic dysfunction, such as urinary and fecal incontinence, may occur with severe spinal cord injury. In peracute cases, signs may develop suddenly, while chronic cases show progressive deterioration. Subtle early indicators include decreased activity, reluctance to jump, and changes in posture.

Differential diagnoses for IVDD include: 1) Spinal neoplasia (e.g., meningioma, lymphoma, osteosarcoma) – typically progressive, with imaging showing lytic or proliferative changes; 2) Fibrocartilaginous embolic myelopathy (FCEM) – acute, non-painful, often asymmetric, with MRI showing ischemic lesions; 3) Discospondylitis – fever, leukocytosis, and radiographic changes with vertebral endplate lysis; 4) Spinal trauma – history of injury, with fractures or luxations on radiographs; 5) Meningomyelitis – infectious or immune-mediated, with CSF analysis showing inflammation; 6) Degenerative myelopathy – progressive, upper motor neuron signs in older large-breed dogs, with normal imaging initially; 7) Lumbosacral stenosis – cauda equina syndrome, with pain on tail manipulation and imaging showing compression; 8) Atlantoaxial instability – neck pain and tetraplegia in young small breeds, with radiographic evidence of instability; 9) Spinal epidural hemorrhage – acute onset, often associated with coagulopathy; 10) Syringomyelia – associated with Chiari-like malformation, with MRI showing fluid-filled cavities.

The diagnostic algorithm for IVDD begins with a thorough history and physical examination, including a complete neurological assessment to localize the lesion. If spinal pain or neurological deficits are present, spinal radiographs may be performed to rule out fractures, luxations, or discospondylitis, but they are not definitive for IVDD. The gold standard for diagnosis is advanced imaging, with MRI being the preferred modality due to its superior soft tissue resolution. MRI can identify disc extrusion or protrusion, spinal cord compression, and intramedullary changes. If MRI is unavailable, CT myelography can be used, which involves injecting contrast into the subarachnoid space to outline the spinal cord. CSF analysis may be performed to rule out inflammatory or infectious diseases, but it is not diagnostic for IVDD. Electrophysiological testing, such as electromyography, is rarely used. The diagnostic algorithm should progress from clinical suspicion to advanced imaging to confirm the diagnosis and guide surgical planning.

Laboratory findings in IVDD are generally non-specific. Complete blood count may show a stress leukogram or mild inflammation. Serum biochemistry is usually within normal limits, but may reveal elevated muscle enzymes (creatine kinase) due to muscle trauma. Urinalysis may show evidence of urinary tract infection, especially in dogs with urinary incontinence. Blood gas analysis may be indicated in severe cases with respiratory compromise. Specific biomarkers, such as C-reactive protein (CRP), may be elevated in acute cases. Cerebrospinal fluid analysis may show albuminocytologic dissociation (elevated protein with normal cell count) in chronic cases, but is not diagnostic. Genetic testing for the FGF4 retrogene can identify at-risk breeds but is not routinely used in clinical diagnosis.

Imaging is essential for the diagnosis and management of IVDD. Spinal radiographs may show calcified discs, narrowed disc spaces, or spondylosis, but are not sensitive or specific. Myelography, though invasive, can demonstrate spinal cord compression by showing deviation or attenuation of the contrast column. Computed tomography (CT) is excellent for detecting calcified disc material and is often used for surgical planning. Magnetic resonance imaging (MRI) is the gold standard, providing detailed images of the spinal cord, disc material, and surrounding soft tissues. MRI findings include disc extrusion or protrusion, spinal cord compression, and increased signal intensity on T2-weighted images indicating edema or myelomalacia. In chronic cases, MRI may show syringomyelia or myelomalacia. Advanced imaging is crucial for localizing the lesion and determining the extent of surgery.

Cytology and histopathology are not typically performed for IVDD diagnosis, but may be used to rule out other diseases. Fine needle aspirates of spinal masses may be performed if neoplasia is suspected. Histopathological examination of surgically removed disc material may show chondroid or fibroid degeneration, with evidence of necrosis and inflammation. In cases of spinal cord injury, histopathology may reveal axonal degeneration, demyelination, and gliosis. Special stains, such as Masson's trichrome, can differentiate collagen types. However, these tests are not routinely used in clinical practice.

Treatment of IVDD depends on the severity of neurological signs. Medical management is recommended for dogs with mild pain (Grade 1) or ambulatory paresis (Grade 2). It includes strict cage rest for 4-6 weeks, anti-inflammatory drugs (e.g., NSAIDs or corticosteroids), and analgesics (e.g., gabapentin, tramadol). Surgical intervention is indicated for dogs with non-ambulatory paresis (Grade 3), paraplegia (Grade 4), or loss of deep pain perception (Grade 5). Surgical techniques include hemilaminectomy, ventral slot, or dorsal laminectomy, depending on the lesion location. The goal is to decompress the spinal cord and remove extruded disc material. Postoperative care includes pain management, physical rehabilitation, and bladder management. In severe cases, euthanasia may be considered if deep pain perception is absent for more than 48 hours, as the prognosis is poor.

The prognosis for IVDD varies with the severity of neurological signs. Dogs with mild pain or ambulatory paresis have a good prognosis with medical management, with 80-90% recovering. Dogs with non-ambulatory paresis that undergo surgery have a 85-95% chance of recovery. Paraplegic dogs with intact deep pain perception have a 80-90% recovery rate, while those with absent deep pain perception have a 50-60% chance of regaining ambulation if surgery is performed within 24 hours. The prognosis worsens if deep pain perception is absent for more than 48 hours, with recovery rates dropping to less than 5%. Negative prognostic indicators include loss of deep pain perception, peracute onset, and severe spinal cord compression. Recurrence rates are low (2-6%) after surgery, but may be higher with medical management.

Follow-up care for IVDD includes regular rechecks at 2, 4, and 8 weeks post-treatment. Neurological examinations should be performed to assess improvement. Serial imaging may be indicated if there is no improvement or worsening. Bladder function should be monitored, and urinary tract infections should be treated promptly. Physical rehabilitation, including passive range of motion exercises, hydrotherapy, and walking aids, is crucial for recovery. Long-term management includes weight control, avoiding high-impact activities, and using ramps instead of stairs. Dogs with residual deficits may require ongoing physiotherapy. Recurrence of clinical signs should prompt immediate re-evaluation.

Pearls: 1) Always perform a thorough neurological examination to localize the lesion before imaging. 2) MRI is the preferred imaging modality for IVDD. 3) Early surgical decompression improves outcomes in non-ambulatory dogs. 4) Strict cage rest is essential for medical management. 5) Monitor for urinary tract infections in paralyzed dogs. Pitfalls: 1) Do not rely solely on radiographs for diagnosis. 2) Avoid corticosteroids in dogs with concurrent NSAID use. 3) Do not delay surgery in dogs with loss of deep pain perception. 4) Do not overlook the possibility of multiple disc herniations. 5) Avoid overexertion during recovery.

Medical management of IVDD includes: 1) NSAIDs: Carprofen (2.2 mg/kg PO q12h) or Meloxicam (0.1 mg/kg PO q24h) for 3-7 days. 2) Corticosteroids: Dexamethasone (0.1-0.2 mg/kg IV q24h) or Prednisone (0.5-1 mg/kg PO q12h) for 3-5 days, then taper. 3) Analgesics: Gabapentin (10-20 mg/kg PO q8-12h) or Tramadol (2-5 mg/kg PO q8-12h). 4) Muscle relaxants: Methocarbamol (15-20 mg/kg PO q8h). 5) Gastroprotectants: Omeprazole (0.5-1 mg/kg PO q24h) or Famotidine (0.5 mg/kg PO q12h) if corticosteroids are used. 6) Antibiotics: Only if urinary tract infection is confirmed. Dosages should be adjusted for renal or hepatic impairment. Contraindications include concurrent use of NSAIDs and corticosteroids. Drug interactions may occur with anticoagulants.

Key studies include: 1) A 2018 study by Olby et al. demonstrated that early surgery (<24 hours) improves recovery in dogs with absent deep pain perception. 2) A 2016 meta-analysis by Moore et al. found that hemilaminectomy is superior to medical management for non-ambulatory dogs. 3) The ACVIM consensus statement on IVDD (2016) recommends MRI for diagnosis and surgical decompression for severe cases. 4) A 2020 study by Jeffery et al. showed that rehabilitation therapy improves functional outcomes. 5) The FGF4 retrogene study by Brown et al. (2017) identified a genetic marker for IVDD risk. These studies support the current diagnostic and therapeutic approaches.